Great to see Immuron's TREAT 002 study in ASH completed. I...

Great to see Immuron's TREAT 002 study in ASH completed. I noticed Intercept's TREAT 001 (currently suspended) study was looking at change in MELD at 6 weeks as the primary endpoint. Our primary endpoint is looking at whether IMM-124E shows a statistically significant change in circulating endotoxin levels at 7 months. However, we are measuring changes in MELD at days 30, 90, and 180 as secondary endpoints, so we will also get sense of how we did on this endpoint as well.

I will say, by and large, Immuron was pretty true to their timeline on the ASH study. Which is no small feat, because there is an article out there on PUBMED somewhere (I would have to go find it again) where Sanyal talks about the difficulty with enrolling ASH patients and getting them to stay on the treatment for such a long period w/o alcohol consumption. Let's see how it worked out. Guess we will know pretty soon.